Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma

被引:138
作者
Maithel, Shishir K. [1 ]
Maloney, Stephen [1 ]
Winston, Corrine [2 ]
Goenen, Mithat [3 ]
D'Angelica, Michael I. [1 ]
DeMatteo, Ronald P. [1 ]
Jarnagin, William R.
Brennan, Murray F. [1 ]
Allen, Peter J. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
关键词
D O I
10.1245/s10434-008-0134-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Staging laparoscopy for patients with radiographically resectable pancreatic adenocarcinoma has been reported to yield an 8-15% finding of unresectable disease. Factors associated with the likelihood of subradiographic unresectable disease have not been clearly defined. Methods: A prospectively maintained pancreatic database was reviewed and patients were identified who underwent staging laparoscopy for radiographically resectable pancreatic adenocarcinoma between January 2000 and December 2006. Preoperative carbohydrate antigen 19-9 (CA 19-9) values were assessed for their association with the presence of subradiographic unresectable disease. Results: Four hundred ninety-one patients underwent staging laparoscopy. Resection was performed in 80% (n = 395). Of the 96 patients with unresectable disease, 75 (78%) had metastases either in the liver (n = 60) or peritoneum (n = 15). Preoperative CA 19-9 values were available for 262 of the 491 patients. Fifty-one of these patients had unresectable disease, of which 78% were due to distant disease. The median preoperative CA 19-9 value for patients who underwent resection was 131 U/ml versus 379 U/ml for those patients with unresectable disease (P = 0.003). A receiver operating characteristics (ROC) curve was developed for preoperative CA 19-9 value and tumor resectability. The statistically optimal cutoff value was determined to be 130 U/ml. Unresectable disease was identified in 38 of the 144 patients (26.4%) with a preoperative CA 19-9 130 U/ml, and in 13 of the 118 patients (11%) with a CA 19-9 < 130 U/ml (P = 0.003). CA 19-9 values greater than 130 U/ml remained a predictor of tumor unresectability on multivariate regression analysis [hazard ratio (HR) 2.70, 95% confidence interval (CI) 1.34-5.44; P = 0.005]. Conclusion: In this study, preoperative CA 19-9 values were strongly associated with the identification of subradiographic unresectable disease. Preoperative CA 19-9 values may allow surgeons to better select patients for staging laparoscopy.
引用
收藏
页码:3512 / 3520
页数:9
相关论文
共 30 条
[1]   Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma [J].
Berger, AC ;
Meszoely, IM ;
Ross, EA ;
Watson, JC ;
Hoffman, JP .
ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (07) :644-649
[2]   The value of laparoscopy in the management of ampullary, duodenal, and distal bile duct tumors [J].
Brooks, AD ;
Mallis, MJ ;
Brennan, MF ;
Conlon, KCP .
JOURNAL OF GASTROINTESTINAL SURGERY, 2002, 6 (02) :139-145
[3]   Staging laparoscopy with laparoscopic ultrasonography: Optimizing resectability in hepatobiliary and pancreatic malignancy [J].
Callery, MP ;
Strasberg, SM ;
Doherty, GM ;
Soper, NJ ;
Norton, JA .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1997, 185 (01) :33-39
[4]   Pancreatic carcinoma: the role of high-resolution multislice spiral CT in the diagnosis and assessment of resectability [J].
Catalano, C ;
Laghi, A ;
Fraioli, F ;
Pediconi, F ;
Napoli, A ;
Danti, M ;
Reitano, I ;
Passariello, R .
EUROPEAN RADIOLOGY, 2003, 13 (01) :149-156
[5]   The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy [J].
Conlon, KC ;
Dougherty, E ;
Klimstra, DS ;
Coit, DG ;
Turnbull, ADM ;
Brennan, MF .
ANNALS OF SURGERY, 1996, 223 (02) :134-140
[6]   Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy [J].
Connor, S ;
Bosonnet, L ;
Alexakis, N ;
Raraty, M ;
Ghaneh, P ;
Sutton, R ;
Neoptolemos, JP .
DIGESTIVE SURGERY, 2005, 22 (1-2) :80-85
[7]   Pancreatic cancer: Value of dual-phase helical CT in assessing resectability [J].
Diehl, SJ ;
Lehmann, KJ ;
Sadick, M ;
Lachmann, R ;
Georgi, M .
RADIOLOGY, 1998, 206 (02) :373-378
[8]   Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma [J].
Ferrone, Cristina R. ;
Finkelstein, Dianne M. ;
Thayer, Sarah P. ;
Muzikansky, Alona ;
Fernandez-del Castillo, Carlos ;
Warshaw, Andrew L. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2897-2902
[9]   The role of diagnostic laparoscopy in pancreatic and periampullary malignancies [J].
Friess, H ;
Kleeff, J ;
Silva, JC ;
Sadowski, C ;
Baer, HU ;
Büchler, MW .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 186 (06) :675-682
[10]   Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma [J].
Fujioka, Shuichi ;
Misawa, Takeyuki ;
Okamoto, Tomoyoshi ;
Gocho, Takeshi ;
Futagawa, Yasuro ;
Ishida, Yuichi ;
Yanaga, Katsuhiko .
JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY, 2007, 14 (06) :539-544